Logo image of APRE

APREA THERAPEUTICS INC (APRE) Stock News

NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD

1.81  -0.13 (-6.7%)

APRE Latest News, Press Relases and Analysis

News Image
23 days ago - Aprea Therapeutics

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in...

News Image
2 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI...

News Image
2 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition

News Image
10 months ago - BusinessInsider

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aprea Therapeutics (NASDAQ:APRE) just reported results for the second quarter o...

News Image
2 months ago - Aprea Therapeutics

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice...

News Image
3 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage...

News Image
4 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage...

News Image
6 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over...

News Image
7 months ago - Aprea Therapeutics

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities ...

News Image
8 months ago - Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is...

News Image
8 months ago - Aprea Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage...

News Image
8 months ago - Aprea Therapeutics

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage...

News Image
8 months ago - Aprea Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage...

News Image
9 months ago - Virtual Investor Conferences

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: NYSE ACST AEMD UNCY ...

News Image
9 months ago - Virtual Investor Conferences

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: VNRX CHRO PLX ACST ...

News Image
9 months ago - Virtual Investor Conferences

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

News Image
9 months ago - Aprea Therapeutics

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage...

News Image
9 months ago - Aprea Therapeutics

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage...

News Image
9 months ago - Aprea Therapeutics

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical...

News Image
10 months ago - InvestorPlace

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

News Image
10 months ago - Aprea Therapeutics

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at...

News Image
a year ago - Aprea Therapeutics

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape...

News Image
a year ago - Aprea Therapeutics

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape